Search results
Results From The WOW.Com Content Network
ESMO has Clinical Practice Guidelines on the following Lung and Chest Tumours: Early and locally advanced non-small-cell lung cancer, Metastatic non-small-cell lung cancer, Thymic epithelial tumours, Malignant pleural mesothelioma, Small-cell lung cancer. They include information on incidence, diagnosis, staging and risk assessment, treatment ...
These updated guidelines on early and locally advanced non-small-cell lung cancer focus on treatment recommendations including follow-up and survivorship. Also covered are new personalised medicine recommendations and new treatment algorithms for locoregional lymph node staging in patients with non-metastatic NSCLC and with clinical stage I ...
This ESMO Clinical Practice Guideline provides key recommendations for managing SCLC. It covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. Treatment algorithms for locoregional, advanced/metastatic and recurrent SCLC are provided. All recommendations were compiled by a multidisciplinary group of ...
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging and systemic and local therapy. Published: 01 September 2021. Authors: J. Remon, J-C. Soria and S. Peters, on behalf of the ESMO Guidelines Committee.
This slide set provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPGs) on the management of early-stage, locally advanced non-small-cell lung cancer (NSCLC). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-up. The ESMO CPGs are intended to provide you with a set ...
The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically relevant topics and are produced by 20-40 key experts in the field. ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
ESMO Consensus Guidelines: Locally-advanced stage III non-small-cell lung cancer (NSCLC) This report from the 2nd ESMO Consensus Conference on Lung Cancer complements existing guidelines and provides recommendations by international experts on guidance substaging stage III NSCLC for decision making, optimal diagnostic work-up, most relevant ...
Ann Oncol. 2023;34 (4):358-376. This ESMO Clinical Practice Guideline provides key recommendations and algorithms for managing non-oncogene addicted mNSCLC. The guideline covers diagnosis, staging, risk assessment, treatment and disease monitoring. ESMO-MCBS scores are given to describe the levels of evidence for treatment choices.
ESMO Consensus Guidelines: Early stage non-small cell lung cancer consensus on diagnosis, treatment and follow-up. Written to complement the ESMO Clinical Practice Guidelines, this manuscript focuses on stage I and II disease. The publication discusses LDCT Screening in non-clinical trial patients, whether or not tissue based diagnosis is ...
The ESMO Interactive Guidelines App is compatible with Android and iOS devices and includes content from the ESMO Pocket Guidelines. These quick reference booklets provide the most important content of the full ESMO Clinical Practice Guidelines on the management of various cancers. Key content includes diagnostic criteria, staging of disease ...